StreetInsider.com News Articles

Form 144 Dyne Therapeutics, Inc. Filed by: Cox John

Tue, 16 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260616/26654195.html

Form 144 Dyne Therapeutics, Inc. Filed by: Cox John

Tue, 16 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260616/26654195.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: HURWITZ EDWARD

Tue, 09 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260609/26624784.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: HURWITZ EDWARD

Tue, 09 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260609/26624784.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Lubner David Charles

Tue, 09 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260609/26624760.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Lubner David Charles

Tue, 09 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260609/26624760.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Kersten Dirk

Tue, 09 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260609/26624744.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Kersten Dirk

Tue, 09 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260609/26624744.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Rhodes Jason P

Tue, 09 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260609/26624749.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Rhodes Jason P

Tue, 09 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260609/26624749.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Incerti Carlo

Tue, 09 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260609/26624735.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Incerti Carlo

Tue, 09 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260609/26624735.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Stehman-Breen Catherine

Tue, 09 Jun 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260609/26624708.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Stehman-Breen Catherine

Tue, 09 Jun 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260609/26624708.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Posner Brian S

Tue, 09 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26624682.html

Form 4 Dyne Therapeutics, Inc. For: Jun 05 Filed by: Posner Brian S

Tue, 09 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26624682.html

Form 8-K Dyne Therapeutics, Inc. For: Jun 05

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617254.html

Form 8-K Dyne Therapeutics, Inc. For: Jun 05

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617254.html

Form 4 Dyne Therapeutics, Inc. For: Jun 03 Filed by: Posner Brian S

Fri, 05 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260605/26611114.html

Form 4 Dyne Therapeutics, Inc. For: Jun 03 Filed by: Posner Brian S

Fri, 05 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260605/26611114.html

Form 8-K Dyne Therapeutics, Inc. For: Jun 03

Wed, 03 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260603/26595446.html

Form 8-K Dyne Therapeutics, Inc. For: Jun 03

Wed, 03 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260603/26595446.html

Dyne Therapeutics completes enrollment in myotonic dystrophy trial

Wed, 03 Jun 2026 07:30:20 -0400

Dyne Therapeutics Inc. (NASDAQ: DYN) announced it has completed enrollment in the registrational expansion cohort of its ACHIEVE trial evaluating z-basivarsen for myotonic dystrophy type 1.

The registrational expansion cohort enrolled 71 participants. The company plans to release topline data from this cohort in the first quarter of 2027 to support a potential Biologics License Application submission for U.S. Accelerated Approval in the third quarter of 2027.

Z-basivarsen, also known as DYNE-101, is an investigational antisense oligonucleotide conjugated to an antigen-binding fragment that targets the transferrin receptor 1. The therapy is designed to reduce toxic nuclear DMPK RNA in patients with DM1.

The

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Wed, 03 Jun 2026 07:30:00 -0400

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the completion of enrollment in the registrational expansion cohort (REC) of the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in individuals with DM1.

“Completing enrollment in the registrational expansion cohort of ACHIEVE is a critical milestone as we advance a potentially best-in-class

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Wed, 03 Jun 2026 07:30:00 -0400

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -